News & Events

Impel NeuroPharma Announces Appointment of Diane Wilfong To Board of Directors

SEATTLE, October 17, 2019 — Impel NeuroPharma today announced that Diane Wilfong has been appointed to the Company’s board of directors. Diane brings 30 years of financial and operations experience in large, multinational companies, including most currently serving as Senior…


Impel NeuroPharma To Present Data From INP104 Clinical Program At The 19th Congress of the International Headache Society

SEATTLE, September 5, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it will present…


Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine

SEATTLE, September 3, 2019 — Impel NeuroPharma today announced the last patient has been enrolled in “STOP-301” (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute…